Format

Send to

Choose Destination
Vaccine. 2018 Jun 22;36(27):3894-3900. doi: 10.1016/j.vaccine.2018.05.095. Epub 2018 May 26.

A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections.

Author information

1
Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
2
Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA; Center for Tropical Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA.
3
Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA.
4
Department of Pathology, University of Texas Medical Branch, Galveston, TX 77550, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA; Center for Tropical Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
5
Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address: john.rose@yale.edu.

Abstract

Chikungunya virus (CHIKV) and Zika virus (ZIKV) have recently expanded their range in the world and caused serious and widespread outbreaks of near pandemic proportions. There are no licensed vaccines that protect against these co-circulating viruses that are transmitted by invasive mosquito vectors. We report here on the development of a single-dose, bivalent experimental vaccine for CHIKV and ZIKV. This vaccine is based on a chimeric vesicular stomatitis virus (VSV) that expresses the CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G) and also expresses the membrane-envelope (ME) glycoproteins of ZIKV. This vaccine induced neutralizing antibody responses to both CHIKV and ZIKV in wild-type mice and in interferon receptor-deficient A129 mice, animal models for CHIKV and ZIKV infection. A single vaccination of A129 mice with the vector protected these mice against infection with both CHIKV and ZIKV. Our single-dose vaccine could provide durable, low-cost protection against both CHIKV and ZIKV for people traveling to or living in areas where both viruses are circulating, which include most tropical regions in the world.

KEYWORDS:

Arbovirus; Microcephaly; Vesicular stomatitis virus

PMID:
29807712
DOI:
10.1016/j.vaccine.2018.05.095
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center